Tissue distribution profiles of multiple major bioactive components in rats after intravenous administration of Xuebijing injection by UHPLC–Q–Orbitrap HRMS

Zuo, Li; Sun, Zhi; Wang, Zhenhui; Ding, Daling; Xu, Tanye; Liu, Liwei; Gao, Li; Du, Shouying; Kang, Jian; Zhang, Xiaojian

doi:10.1002/bmc.4400

Cited by 12 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like artemisinin used for malaria treatment, XBJ used as an injection is also a medicinal ingredient extracted from a traditional Chinese medicine. Its main components include hydroxysa or yellow A, ligustrazine, salvianic acid A, ferulic acid, paeoni orin, and protocatechuic aldehyde [23]. XBJ can effectively improve the prognosis of patients with paraquat poisoning, and the potential mechanisms include the following.First, by inhibiting the overexpression of proin ammatory factors, such as tumor necrosis factor α (TNF-α), platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1),transforming growth factor-β1 (TGF-β1), interleukin (IL)-1, and IL-6; blocking the TGF-β1/ERK signaling pathway [24]; promoting the expression of anti-in ammatory factors, such as IL-10; re-establishing the balance of in ammatory/anti-in ammatory transmitters; attenuating in ammation; and exerting organ protection.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of combined use of Xuebijing and ulinastatin for paraquat poisoning: A systematic review and meta-analysis of randomized controlled trials

Xu¹,

Ding²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: There are no clinically effective antidotes for paraquat poisoning, which progresses rapidly with a poor prognosis and high mortality. The addition of Xuebijing (XBJ) and ulinastatin (UTI) combination to conventional therapy has been reported as a novel treatment approach.Objective: To compare the effectiveness of Xuebijing combined with ulinastatin and conventional treatment group in the treatment of paraquat poisoning.Methods: The CNKI, VIP, WanFang, PubMed, EMBASE, and MEDLINE databases were searched for publications on randomized controlled clinical trials that compared the XBJ+UTI combination as an additional treatment to conventional therapy versus conventional therapy alone.Results: Quality assessment of the selected publications was performed and data were extracted for analysis. The final analysis included five publications, reporting 588 patients with paraquat poisoning. The control and XBJ+UTI groups comprised 294 patients each; 138 and 100 patients in the control and conventional therapy plus XBJ+UTI groups died, respectively. The combined analysis showed that the mortality relative risk (RR) was 0.72 and I2 was 46.2%. Three publications reported of pulmonary fibrosis (PF) and multiple organ dysfunction syndrome (MODS), in which 134 patients were included in each of the control and XBJ+UTI groups. MODS occurred in 117 and 88 patients in the control and conventional therapy plus XBJ+UTI groups, respectively. The combined analysis using the random-effects model showed that the RR was 0.75 and I2 was 0.0%. PF occurred in 99 and 68 patients in the control and conventional therapy plus XBJ+UTI groups, respectively. The combined analysis using the random-effects model showed that the RR was 0.69 and I2 was 0.0%.Conclusions: We preliminarily demonstrated that compared with those of conventional therapy alone, the addition of XBJ+UTI combination for the treatment of paraquat poisoning could reduce the mortality rate and incidence of MODS and PF.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of combined use of Xuebijing and ulinastatin for paraquat poisoning: A systematic review and meta-analysis of randomized controlled trials

Xu¹,

Ding²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Among these compounds, senkyunolide I-7-O-â-glucuronide, 3-O-methyltanshinol, protocatechuic acid, and 3-O-methylsalvianolic acid B are the in vivo metabolites of senkyunolide I, tanshinol, protocatechuic aldehyde, and salvianolic acid B, respectively; the unchanged compound protocatechuic aldehyde could not be detected in human plasma samples [29,[49][50][51]. Several other research groups also measured circulating herbal compounds in their unchanged forms in rats receiving XueBiJing based on developed bioanalytical assays [52][53][54][55]. Zuo et al investigated the tissue distributions of several bioactive compounds in rats after they intravenously received XBJ, and the levels of exposure to four compounds (i.e., hydroxysafflor yellow A, paeoniflorin, ferulic acid, and benzoylpaeoniflorin) were found to be high in the kidneys, liver, stomach, and intestines [52].…”

Section: Chinese Herbal Medicinesmentioning

confidence: 96%

Research Progress in Chinese Herbal Medicines for Treatment of Sepsis: Pharmacological Action, Phytochemistry, and Pharmacokinetics

Cheng

2021

IJMS

View full text Add to dashboard Cite

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection; the pathophysiology of sepsis is complex. The incidence of sepsis is steadily increasing, with worldwide mortality ranging between 30% and 50%. Current treatment approaches mainly rely on the timely and appropriate administration of antimicrobials and supportive therapies, but the search for pharmacotherapies modulating the host response has been unsuccessful. Chinese herbal medicines, i.e., Chinese patent medicines, Chinese herbal prescriptions, and single Chinese herbs, play an important role in the treatment of sepsis through multicomponent, multipathway, and multitargeting abilities and have been officially recommended for the management of COVID-19. Chinese herbal medicines have therapeutic actions promising for the treatment of sepsis; basic scientific research on these medicines is increasing. However, the material bases of most Chinese herbal medicines and their underlying mechanisms of action have not yet been fully elucidated. This review summarizes the current studies of Chinese herbal medicines used for the treatment of sepsis in terms of clinical efficacy and safety, pharmacological activity, phytochemistry, bioactive constituents, mechanisms of action, and pharmacokinetics, to provide an important foundation for clarifying the pathogenesis of sepsis and developing novel antisepsis drugs based on Chinese herbal medicines.

show abstract

“…Diels (Danggui). Ultra-high-performance liquid chromatography coupled with quadrupole Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) indicates that the primary components of XBJ are hydroxysafflor yellow A, oxypaeoniforin, senkyunolide I, and benzoylpaeoniflorin [ 77 ]. XBJ has been approved for use in the treatment of severe infections (sepsis) in critically ill patients (China Food and Drug Administration; Beijing, China, Number Z20040033).…”

Section: Treatment Of Covid-19 With Tcmmentioning

confidence: 99%

Current status of traditional Chinese medicine for the treatment of COVID-19 in China

et al. 2021

View full text Add to dashboard Cite

An ongoing outbreak of severe respiratory illness and pneumonia caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) commenced in December 2019, and the disease was named as coronavirus disease 2019 (COVID-19). Soon after, scientists identified the characteristics of SARS-CoV-2, including its genome sequence and protein structure. The clinical manifestations of COVID-19 have now been established; and nucleic acid amplification is used for the direct determination of the virus, whereas immunoassays can determine the antibodies against SARS-CoV-2. Clinical trials of several antiviral drugs are ongoing. However, there is still no specific drugs to treat COVID-19. Traditional Chinese medicine (TCM) was used in the treatment of COVID-19 during the early stages of the outbreak in China. Some ancient TCM prescriptions, which were efficacious in the treatment of severe acute respiratory syndrome (SARS) in 2002–03 and the influenza pandemic (H1N1) of 2009, have been improved by experienced TCM practitioners for the treatment of COVID-19 based on their clinical symptoms. These developed new prescriptions include Lianhua Qingwen capsules/granules, Jinhua Qinggan granules and XueBiJing injection, among others. In this review, we have summarized the presenting features of SARS-CoV-2, the clinical characteristics of COVID-19, and the progress in the treatment of COVID-19 using TCMs.

show abstract

Tissue distribution profiles of multiple major bioactive components in rats after intravenous administration of Xuebijing injection by UHPLC–Q–Orbitrap HRMS

Cited by 12 publications

References 22 publications

Efficacy of combined use of Xuebijing and ulinastatin for paraquat poisoning: A systematic review and meta-analysis of randomized controlled trials

Efficacy of combined use of Xuebijing and ulinastatin for paraquat poisoning: A systematic review and meta-analysis of randomized controlled trials

Research Progress in Chinese Herbal Medicines for Treatment of Sepsis: Pharmacological Action, Phytochemistry, and Pharmacokinetics

Current status of traditional Chinese medicine for the treatment of COVID-19 in China

Contact Info

Product

Resources

About